XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| XBIT | XBiotech Inc. | 2025-10-16 15:10:05 | 2.49 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XBIT | 0001626878 | XBiotech Inc. | US98400H1023 | 5299002WACAY28TQAS52 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | A1 | 5217 WINNEBAGO LANE | AUSTIN | TX | 78744 | UNITED STATES | US | 512-386-2900 | 5217 WINNEBAGO LANE, AUSTIN, TX, 78744 | 5217 WINNEBAGO LANE, AUSTIN, TX, 78744 | — | Biopharmaceutical | 2005 | John Simard | — | http://xbiotech.com | 121,869,724 | 30,487,731 | 30,487,731 | XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases. | 2025-10-10 22:59:01 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 121,869,724 | -18,607,094 | -13.2457 | 30,487,731 | 36,850 | 0.121 |
| 2023 | 140,476,818 | 7,668,412 | 5.774 | 30,450,881 | 11,606 | 0.0381 |
| 2022 | 132,808,406 | -295,634,174 | -69.0021 | 30,439,275 | 0 | 0 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Angela Hu | Director | 2024 | 200,000 | 80,000 | — | — | 5,419 | 285,419 |
| John Simard | Chief Executive Officer, President | 2024 | 1,205,083 | 5,030,000 | — | — | 10,498 | 6,245,581 |
| Sushma Shivaswamy | Chief Scientific Officer | 2024 | 450,000 | 197,047 | — | — | 10,498 | 657,572 |
| Sushma Shivaswamy | Chief Scientific Officer | 2023 | 445,190 | 0 | — | — | 4,800 | 720,499 |
| John Simard | Chief Executive Officer, President | 2023 | 1,065,440 | 4,480,000 | — | — | 11,041 | 5,556,481 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 92 |
| 2023 | 82 |
| 2022 | 85 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | — | 0 | 4,010,000 |
| Cost Of Revenue | — | 0 | 651,000 |
| Gross Profit | — | 0 | 3,359,000 |
| Research And Development Expenses | 37,757,000 | 32,848,000 | 31,544,000 |
| General And Administrative Expenses | 4,714,000 | 4,662,000 | 6,305,000 |
| Operating Expenses | — | 37,510,000 | 37,849,000 |
| Operating Income | -42,471,000 | -37,510,000 | -34,490,000 |
| Net Income | -38,531,000 | -24,557,000 | -32,900,000 |
| Earnings Per Share Basic | -1.26 | -0.81 | -1.08 |
| Earnings Per Share Diluted | -1.26 | -0.81 | -1.08 |
| Weighted Average Shares Outstanding Basic | 30,460,980 | 30,438,459 | 30,439,275 |
| Weighted Average Shares Outstanding Diluted | 30,460,980 | 30,438,459 | 30,439,275 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 172,677,000 | 200,023,000 | 157,306,000 |
| Marketable Securities Current | — | 0 | 60,172,000 |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | 158,000 | 75,000 | 548,000 |
| Other Assets Current | — | — | — |
| Total Assets Current | 174,567,000 | 201,718,000 | 219,843,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 24,526,000 | 24,897,000 | 26,260,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 24,526,000 | 24,897,000 | 26,260,000 |
| Total Assets | 199,093,000 | 226,615,000 | 246,103,000 |
| Accounts Payable | 2,223,000 | 2,516,000 | 2,408,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 2,632,000 | 3,501,000 | 1,603,000 |
| Total Liabilities Current | 15,105,000 | 6,100,000 | 4,066,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 1,720,000 | 1,669,000 | 1,635,000 |
| Total Liabilities | 16,825,000 | 7,769,000 | 5,701,000 |
| Common Stock | 273,105,000 | 271,152,000 | 267,325,000 |
| Retained Earnings | -90,837,000 | -52,306,000 | -27,749,000 |
| Accumulated Other Comprehensive Income | — | 0 | 826,000 |
| Total Shareholders Equity | 182,268,000 | 218,846,000 | 240,402,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 1,745,000 | 1,744,000 | 2,614,000 |
| Share Based Compensation Expense | 1,753,000 | 3,262,000 | 5,062,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | 0 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | 83,000 | -473,000 | -8,556,000 |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -364,000 | 91,000 | 357,000 |
| Change In Other Liabilities | -877,000 | 1,895,000 | 229,000 |
| Cash From Operating Activities | -30,963,000 | -18,725,000 | -14,824,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 1,304,000 | 362,000 | 585,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -1,304,000 | 61,497,000 | -63,892,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | 0 |
| Issuance Of Common Stock | — | 4,800 | — |
| Repurchase Of Common Stock | 0 | 14,000 | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 200,000 | 5,000 | 0 |
| Cash From Financing Activities | 10,450,000 | -9,000 | 0 |
| Change In Cash | -27,346,000 | 42,717,000 | -79,677,000 |
| Cash At End Of Period | 172,677,000 | 200,023,000 | 157,306,000 |
| Income Taxes Paid | 85,000 | — | — |
| Interest Paid | 400,000 | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -1.26 | -0.81 | -1.08 |
| Price To Earnings Ratio | -3.1349 | -4.9383 | -3.25 |
| Earnings Growth Rate | 55.5556 | -25 | 86.2069 |
| Price Earnings To Growth Ratio | -0.0564 | 0.1975 | -0.0377 |
| Book Value Per Share | 5.9837 | 7.1898 | 7.8978 |
| Price To Book Ratio | 0.6601 | 0.5563 | 0.4444 |
| Ebitda | -36,701,000 | -22,813,000 | -30,286,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | 0 |
| Dividend Payout Ratio | — | — | 0 |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 1,374,000 | 381,000 | 567,000 |
| Free Cash Flow | -32,337,000 | -19,106,000 | -15,391,000 |
| Return On Equity | -0.2114 | -0.1122 | -0.1369 |
| One Year Beta | 1.1707 | 0.8413 | 0.9996 |
| Three Year Beta | 1.0041 | 0.9665 | 0.9145 |
| Five Year Beta | 0.9256 | 0.9112 | 0.8051 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| SIMARD JOHN | Director, Chief Executive Officer, 10% owner | 2025-03-17 | 1,026,228 | A | 1,896,609 |
| SIMARD JOHN | Director, Chief Executive Officer, 10% owner | 2025-01-31 | 2,470,355 | D | 870,381 |
| Libby Peter | Director | 2024-06-20 | 37,500 | A | 37,500 |
| MacAdam Donald H. | Director | 2024-06-20 | 37,500 | A | 37,500 |
| Waldin Jan-Paul | Director | 2024-06-20 | 37,500 | A | 37,500 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Thomasville National Bank | 2025-09-30 | 35,511 | 13,350 | 2.66 |
| Squarepoint Ops LLC | 2025-06-30 | 118,135 | 39,776 | 2.97 |
| NATIONAL BANK OF CANADA /FI/ | 2025-06-30 | 74,000 | 25,000 | 2.96 |
| MORGAN STANLEY | 2025-06-30 | 254,841 | 85,805 | 2.97 |
| Tower Research Capital LLC (TRC) | 2025-06-30 | 27,716 | 9,332 | 2.97 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| DFA INVESTMENT DIMENSIONS GROUP INC | 2025-07-31 | U.S. MICRO CAP PORTFOLIO - INSTITUTIONAL CLASS | DFSCX | 15,235 | 44,181.5 | 0.0007 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 2025-07-31 | U.S. CORE EQUITY 1 PORTFOLIO - INSTITUTIONAL CLASS | DFEOX | 1,680 | 4,872 | 0.0 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 2025-07-31 | U.S. CORE EQUITY 2 PORTFOLIO - INSTITUTIONAL CLASS | DFQTX | 9,859 | 28,591.1 | 0.0001 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 2025-07-31 | U.S. VECTOR EQUITY PORTFOLIO - INSTITUTIONAL CLASS | DFVEX | 1,910 | 5,539 | 0.0001 |
| EA Series Trust | 2025-06-30 | EA Bridgeway Omni Small-Cap Value ETF | BSVO | 59,326 | 176,198.22 | 0.01 |